Jubilant Q4 net at Rs 51.68 cr

Our Bureau New Delhi | Updated on May 10, 2011 Published on May 10, 2011


Jubilant Life Sciences (formerly Jubilant Organosys) reported a net profit at Rs 51.68 crore for the quarter ended March 31, 2011.

Net sales were at Rs 560.39 crore (Rs 601.9 crore).

For the year ended March 2011, net profit declined to Rs 279.63 crore from Rs 363.10 crore in the previous year. Net sales also declined to Rs 2,200.89 crore (Rs 2,456.06 crore).

To pay 200%

The company declared equity dividend of 200 per cent for 2010-11.

The company implemented the scheme of amalgamation and demerger among Jubilant Life Sciences, Specialty Molecules Ltd, Pace Marketing Specialties Ltd and Jubilant Industries (formerly Hitech Shiksha Ltd) during November 2010, effective from April 1, 2010. Thus the figures are not strictly comparable. Post-demerger of agri and performance polymer business, JLSL has only pharmaceutical segment.

Revenues for Life Science products reached Rs 2,685 crore and contributed 78 per cent to the total revenue. It grew 9 per cent in the year with good volume growth of over 15 per cent across products.

Mr Shyam S. Bhartia, Chairman and Managing Director, said, “In financial year 2011 the company recorded good revenue growth in products business driven by a volume growth of 16 per cent across products. However, growth in service business is muted due to one-time revenue opportunity in previous year and slowdown in clinical research business. In FY2012, we expect to deliver a robust sales growth and better margins across all the businesses on account of increased capacity utilisation, commissioning of new plants, new launches and expansion of market geographies.”

Published on May 10, 2011
This article is closed for comments.
Please Email the Editor